#USA #Class Action #Philadelphia #Settlement #Generic Drugs

Class Action Settlement for Prescription Generic Drugs

Fine, Kaplan and Black, R.P.C., has recently announced a significant class action settlement related to specific prescription generic drugs purchased in the United States between May 1, 2009, and December 31, 2019. The announcement is particularly important for individuals who either paid or were reimbursed for these medications during this period.

Overview of the Settlement

The settlement has been preliminarily approved by a federal court and is part of ongoing litigation against Sun Pharmaceutical Industries, Inc. and Taro Pharmaceuticals U.S.A. The settlement fund has been established to compensate eligible members of the class. Notably, the litigation alleges that these generic drug manufacturers violated federal and state antitrust laws, leading to inflated costs borne by consumers and third-party payers, such as insurance companies and employers.

Are You Eligible?

Individuals who may qualify as members of the settlement class include end payers who directly or indirectly paid for any of the specified prescription generic drugs during the stipulated time frame, except in Indiana and Ohio. If you purchased such drugs for personal use and not for resale, you could be a member of the settlement class. A detailed notice containing a complete list of eligible drugs, an overview of the defendants, and specifics about the settlement agreement has been made available on the official settlement website.

Settlement Amount

According to the proposed settlement agreement, a total of $200 million will be allocated to a settlement fund intended to provide compensation to claimants. However, reductions to this fund may occur under certain conditions. The fund will also cover administrative costs (up to $750,000) and legal fees (which could be as high as one-third of the total fund plus interest). The settlement also provides for potential future expenses related to ongoing litigation against any remaining defendants.

Claims Process

To receive compensation from this settlement, class members must adhere to a specific claims process that will begin following final approval by the court. Details regarding the distribution plan have been published online and will guide eligible participants on how to navigate the claims process. Class members are encouraged to register on the settlement website to stay updated on critical information, including when and how to submit claims.

Your Options as a Class Member

As a member of the class, you can choose to remain in the settlement or opt-out. Choosing not to act will leave you as part of the class and eligible for settlement benefits. However, if you prefer to retain your right to sue Sun and Taro separately, you must formally exclude yourself from the class. If class members disagree with any part of the settlement agreement or proposed distributions, they have the right to object before a specified deadline.

Important Dates

The court will hold a fairness hearing on January 15, 2026, to determine whether the settlement agreement and distribution plans should be approved. Individuals wishing to attend this hearing must notify the court ahead of time, and while hiring an attorney is optional, any associated costs will be the responsibility of the individual.

For further information about the settlement, eligible members can call 1-877-316-0171 or visit the dedicated website for updates and details. As the process unfolds, the outcomes from this settlement could lead to significant financial relief for many affected consumers who struggled with the costs of their medications during the outlined years.